文献速递前列腺癌

CHHiP 试验 5 年患者报告结局:中度大分割放疗安全性获验证

Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).
PubMed 文献 · Eur Urol Oncol · 2021-09-03

CHHiP Ⅲ 期随机试验比较常规放疗(74 Gy/37 次)与中度大分割放疗(60 Gy/20 次或 57 Gy/19 次)在局限期前列腺癌中的 5 年患者报告结局。结果显示三种方案在肠道、泌尿及性功能困扰方面总体相似,中度大分割放疗可推荐为中间风险局限期前列腺癌的标准治疗。

要点

  • 5 年肠道「中度或重度」困扰发生率各方案均低(5.4%–7.6%),无显著差异。
  • 泌尿与性功能困扰在三种方案间 5 年时相似。
  • 大分割方案较 74 Gy 更少出现性功能困扰加重。

核心结论

  • 5 年随访证实三种放疗方案在患者报告的肠道、泌尿及性功能困扰方面总体相似。

研究设计与样本

  • Ⅲ 期随机对照试验 CHHiP 于 2002–2011 年入组 3216 例局限期前列腺癌(cT1b-T3aN0M0)。
  • 生活质量子研究入组 2100 例,随访至放疗后 5 年,分析采用 2016 年 8 月 26 日数据快照。

主要发现

  • 5 年总体「中度或重度」肠道困扰发生率:74 Gy 组 19/349(5.4%)、60 Gy 组 29/381(7.6%)、57 Gy 组 21/393(5.3%),无统计学显著差异。
  • 5 年时总体泌尿或性功能困扰在三种方案间相似,且肠道与泌尿症状从 2 年至 5 年保持稳定。
  • 与 74 Gy 相比,大分割方案较少出现性功能困扰评分加重:60 Gy 的 OR 为 0.55(0.30–0.99),p=0.009;57 Gy 的 OR 为 0.52(0.29–0.94),p=0.004。
  • 5 年时三种方案的一般生活质量评分相似。

关键数值与推荐

  • 推荐中度大分割放疗作为中间风险局限期前列腺癌的标准治疗。

临床怎么用

  • 临床可依据 CHHiP 5 年患者报告结局,向患者说明中度大分割放疗在肠道、泌尿及性功能方面与常规放疗同样安全。

局限性

  • 5 年问卷仅从 1957 例存活患者中获得 1141 份(58%),存在缺失数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Moderate hypofractionation is the recommended standard of care for localised prostate cancer following the results of trials including Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer (CHHiP). Evaluation of long-term patient-reported outcomes (PROs) is important to confirm safety and enhance patient information. OBJECTIVE: To determine whether 5-yr PROs from the CHHiP quality of life (QoL) substudy confirm 2-yr findings and assess patterns over follow-up. DESIGN, SETTING, AND PARTICIPANTS: A phase III randomised controlled trial recruited from 2002 to 2011. The QoL substudy completed accrual in 2009; participants were followed up to 5 yr after radiotherapy. Analyses used data snapshot taken on August 26, 2016. A total of 71 radiotherapy centres were included in the study (UK, Republic of Ireland, Switzerland, and New Zealand); all 57 UK centres participated in the QoL substudy. CHHiP recruited 3216 men with localised prostate cancer (cT1b-T3aN0M0). INTERVENTION: Conventional (74 Gy/37 fractions/7.4 wk) or hypofractionated radiotherapy (60 Gy/20 fractions/4 wk or 57 Gy/19 fractions/3.8 wk) was delivered with intensity-modulated techniques. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: University of California Los Angeles Prostate Cancer Index, Short Form 36 and Functional Assessment of Cancer Therapy-Prostate, or Expanded Prostate Cancer Index Composite and Short Form 12 questionnaires were administered at baseline, before radiotherapy, at 10 wk, and at 6, 12, 18, 24, 36, 48, and 60 mo after radiotherapy. The QoL primary endpoint was overall bowel bother. RESULTS AND LIMITATIONS: The QoL substudy recruited 2100 patients; 1141 5-yr forms were available from 1957 patients still alive (58%). There were no statistically significant differences in 5-yr prevalence of overall "moderate or big" bowel bother: 19/349 (5.4%), 29/381 (7.6%), and 21/393 (5.3%) for 74, 60, and 57 Gy, respectively; overall urinary or sexual bother at 5 yr was similar between schedules. Bowel and urinary symptoms remained stable from 2 to 5 yr for all schedules. Some evidence of worsening overall sexual bother from baseline to 5 yr was less likely in the hypofractionated schedules compared with 74 Gy (odds ratios for increase in bother score vs 74 Gy: 0.55 [0.30-0.99], p = 0.009 for 60 Gy, and 0.52 [0.29-0.94], p = 0.004 for 57 Gy). General QoL scores were similar between schedules at 5 yr. CONCLUSIONS: Longer follow-up confirms earlier findings, with similar patient-reported bowel, urinary, and sexual problems between schedules overall. The continued low incidence of moderate or high bother confirms that moderate hypofractionation should be the standard of care for intermediate-risk localised prostate cancer. PATIENT SUMMARY: We looked at patient-reported outcomes up to 5 yr after treatment in a trial of different radiotherapy schedules for prostate cancer. The findings confirmed that shorter radiotherapy schedules were as safe as standard radiotherapy in terms of bowel, urinary, and sexual problems. TAKE HOME MESSAGE: Bowel, urinary, and sexual symptoms were similar between schedules up to 5 yr. The continued low incidence of moderate/high bother confirms that moderate hypofractionated radiotherapy should be considered the standard of care for men with intermediate-risk prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Staffurth JN, Haviland JS, Wilkins A, et al. Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016). Eur Urol Oncol. 2021. PMID: 34489210. doi:10.1016/j.euo.2021.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。